Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 0.63 |
| ▸ | CCND1 | P24385 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526317 | 0.84 | LMNA (0.73) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL29684637 | 0.84 | LMNA (0.73) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL13265611 | 0.83 | LMNA (0.71) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL12881191 | 0.83 | LMNA (0.71) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL29955957 | 0.82 | KMT2A (0.71) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL1519806 | 0.82 | KMT2A (0.71) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL12881193 | 0.82 | LMNA (0.69) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL10203635 | 0.81 | LMNA (0.69) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL1520321 | 0.80 | LMNA (0.67) | LMNACDK4CCND1KMT2AMAPK1 | |
| SCHEMBL1120445 | 0.80 | CDK4 (0.76) | LMNACDK4CCND1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | claimed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | claimed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | claimed |
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| US-RE47009-E1 | HDAC inhibitors and therapeutic methods using the same | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2018-08-28 | — | — | US | disclosed |
| US-9249087-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2670733-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106343-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012106343-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-08-09 | — | — | WO | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4273782-A | FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HDAC1, HDAC9, HDAC8 | LMNA 2543/4885CDK4 992/4885CCND1 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.